Lupin launches Dapagliflozin Tablets in US
This launch follows the receipt of approval for its ANDA from the USFDA
Lupin has launched Dapagliflozin Tablets, 5 mg and 10 mg, in the United States (US) following the approval for its Abbreviated New Drug Application (ANDA) from the United States Food and Drug Administration (USFDA) as bioequivalent to Farxiga for the indications in the approved labeling.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
